辉瑞(PFE.US)行政总裁Albert Bourla表示,美国制药业需要与中国合作,过去十年中国的快速研发流程已占全球药物研发的30%。他称,在生物制药领域上,中国正已惊人的发展速度、成本及规模带动全球竞争格局的转变,中国目前拥有约1,200种新型候选药物,而十年前只有约60种。在中美贸易战下,辉瑞在今年较早时与三生制药(01530.HK)达成协议,获得一项实验性癌症治疗药物的许可,将预付...
Source Link辉瑞(PFE.US)行政总裁Albert Bourla表示,美国制药业需要与中国合作,过去十年中国的快速研发流程已占全球药物研发的30%。他称,在生物制药领域上,中国正已惊人的发展速度、成本及规模带动全球竞争格局的转变,中国目前拥有约1,200种新型候选药物,而十年前只有约60种。在中美贸易战下,辉瑞在今年较早时与三生制药(01530.HK)达成协议,获得一项实验性癌症治疗药物的许可,将预付...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.